TABLE 1

Characteristics of the study population

No COPD (n=98)UCOPD (n=39)p-value
Age years63±1169±8<0.01
Male n (%)83 (85)32 (82)0.8
BMI k·m−228±427±40.2
Diabetes n (%)21 (21)11 (28)0.5
Hypertension n (%)67 (68)25 (64)0.7
Hyperlipidaemia n (%)55 (56)17 (44)0.2
Current smoker n (%)44 (45)17 (44)0.9
Previous smoker n (%)54 (55)22 (56)
Prior MI n (%)16 (16)8 (21)0.3
Prior PCI n (%)18 (18)6 (15)0.8
Prior CABG n (%)5 (5)2 (5)0.9
STEMI n (%)40 (41)19 (49)0.6
LVEF %52±950±90.2
Laboratory data at baseline
 White blood cells u·μL−110±311±30.7
 Haemoglobin g·dL−113±213±20.6
 Platelets u·μL−1227 [189–266]223 [192–280]0.6
Cardiovascular therapy n (%)
 Aspirin97 (99)39 (100)0.9
 Ticagrelor55 (56)20 (52)0.6
 Other P2Y12 inhibitor43 (44)19 (48)
  Clopidogrel33 (34)14 (36)0.8
  Prasugrel10 (10)5 (12)0.8
 Beta-blocker84 (86)35 (90)0.8
 ACE inhibitor/ARB88 (90)37 (95)0.5
 Statin96 (98)37 (95)0.3
 Calcium channel blockers5 (5)2 (5)0.9
 Nitrates2 (2)1 (2)0.9
 Proton pump inhibitor#51 (52)20 (51)0.9
Biological parameters %
 Rate of apoptosis9.2±413.2±3<0.001
  Patients receiving ticagrelor7.7±312.2±2<0.001
  Patients receiving other P2Y12 inhibitors11.1±514.2±30.0004
 On-treatment PR after ADP stimulus32±1442±17<0.001
  Patients receiving ticagrelor24±1128±90.3
  Patients receiving other P2Y12 inhibitors41±1157±7<0.001
 On-treatment PR after AA stimulus14±2122±20<0.001

Data are presented as mean±sd, unless otherwise stated.#: pantoprazole was the only proton pump inhibitor administered. COPD: chronic obstructive pulmonary disease; UCOPD: undiagnosed/unknown COPD; BMI: body mass index; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; STEMI: ST-segment elevation MI; LVEF: left ventricular ejection fraction; ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker; PR: platelet reactivity; ADP: adenosine diphosphate; AA: arachidonic acid.